Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

us recorded revenue during the first quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the first quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $2.5 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its guidance for 2008 cash burn of $40 million to $60 million. The Company also stated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in tables 2 and 3, and are primarily due to:

-- Pre-tax stock compensation expense

-- Pre-tax charges for preferred stock accretion

-- Pre-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MDV-Mohr Davidow Ventures, a,leading Silicon Valley venture capital ... Dan Riskin to the firm as Executive-in-Residence and,Entrepreneur-in-Residence, ... provide healthcare providers and consumers more effective,ways to ... diagnosis to the,treatment of disease. , ...
... Switzerland and BANGALORE, India, November 20 ... development,specialist that focuses on serious medical ... Technologies Ltd (Aurigene), a,Bangalore-based fully integrated, ... peptide drug discovery and development from ...
... Nov. 19 Serica Technologies, Inc., a,growth-stage ... tissue regeneration, today announced that it has ... standards,required for medical device manufacturers. ISO certification ... regulatory bodies worldwide as proof of an,effective ...
Cached Biology Technology:MDV Expands Team Pursuing Advances in Personalized Medicine 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 2Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 4
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
(Date:4/15/2014)... New Zealand,s pastoral landscapes are some of the loveliest ... threat. Many of the country,s pasture soils have become ... metal, which is then eaten by the cattle and ... to New Zealand; cadmium-enriched soils being reported worldwide. , ... unsafe levels in meat and dairy products, human health ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... 2011) Researchers looking to find a root cause for ... a novel investigative approach that borders on science fiction as ... the nation,s No. 1 killer. The National Institutes of ... Scripps Translational Science Institute (STSI) of San Diego and Sangamo ...
... wide variety of new cut flower cultivars and species ... University and the Association of Specialty Cut Flower Growers. ... United States and Canada, provides valuable production and marketing ... team from North Carolina State University undertook a multiyear ...
... Stephane Len, both researchers at the IRMES (Institut de ... France), have published their findings in Age , ... the evolution of performances in elite athletes and chess ... developed by the laboratory, and suggests that changes in ...
Cached Biology News:Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 2Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 3Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 4Extending the vase life of cut flowers: Pre-treatments and preservatives studied 2Evolution of sport performances follows a physiological law 2
... able to handle larger sample volumes, automate infusions, ... interface with telemetry systems. The AccuSampler LA ... pigs, and primates. The system may be ... computer can be located outside the animal room ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... key to successful cell culture or fermentation ... during the process, and make rapid adjustments ... Nova BioProfile Chemistry Analyzers provide immediate analysis ... cell culture and fermentation media. BioProfile analyzers ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
Biology Products: